Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEdoardo CampodonicoMCMelania CelliAAAndrea Assanelli

Discussion

Loading...

Member takes

Overview

Observational analysis found remission in 16 of 23 patients with secondary CNS lymphoma treated with CAR-T, suggesting effective salvage treatment post-chemotherapy.

Key Points

  • 16 of 23 patients with secondary CNS lymphoma achieved remission after CAR-T therapy, indicating its potential effectiveness.
  • At 8 months follow-up, 12 remaining relapse-free points to the treatment's promise.
  • Analysis focused on a tailored approach among patients, with multidimensional team evaluation for CAR-T eligibility.
  • Implications highlight the necessity for personalized treatment strategies to mitigate toxicity in SCNSL patients.

Cite This Study

Campodonico et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8ebhttps://doi.org/10.1182/blood-2025-7241
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  2. 2Tandem combination of ASCT and CAR T‐cell therapy in highly refractory CNS lymphomas2025
  3. 3Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement2025
  4. 4Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma2026 · 6 citations
  5. 5P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK2025